Literature DB >> 16980441

Targeting B cells in Graves' disease.

Su He Wang1, James R Baker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980441     DOI: 10.1210/en.2006-0852

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  5 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.

Authors:  Rina Bhatt; Christine C Nelson; Raymond S Douglas
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

Review 3.  Rituximab for thyroid-associated ophthalmopathy.

Authors:  Swan Kang; Shirin Hamed Azzam; Neda Minakaran; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

4.  Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Authors:  Xiaomei Liu; Hui Guo; Juan Liu; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

Review 5.  Hyperthyroidism in childhood: causes, when and how to treat.

Authors:  Juliane Léger; Jean Claude Carel
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.